00:00
51:23
This is part 2 of our event with BioIDEA: Biotech vs COVID-19

BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.

Our panelists included Elena Diez Cecilia, Director of Business Development and R&D Strategy at A2A Pharmaceuticals, Ed Painter, Chairman and CIO of A2A Pharmaceuticals; Peter Leonardi, CEO and Founder of OmniCyte; and our very own Andrew Satz, CEO and Co-Founder of EVQLV.

More from BioIDEA: https://bioidea.co/
More from A2A Pharmaceuticals: https://a2apharma.com/
More form OmniCyte: https://omnicyte.com/
More from EVQLV: https://evqlv.com/
This is part 2 of our event with BioIDEA: Biotech vs COVID-19 BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19. Our panelists included Elena Diez Cecilia, Director of Business Development and R&D Strategy at A2A Pharmaceuticals, Ed Painter, Chairman and CIO of A2A Pharmaceuticals; Peter Leonardi, CEO and Founder of OmniCyte; and our very own Andrew Satz, CEO and Co-Founder of EVQLV. More from BioIDEA: https://bioidea.co/ More from A2A Pharmaceuticals: https://a2apharma.com/ More form OmniCyte: https://omnicyte.com/ More from EVQLV: https://evqlv.com/ read more read less

3 years ago #a2a_pharmaceuticals, #andrew_satz, #bioidea, #biotech, #coronavirus, #covid19, #evqlv, #omnicyte, #sars, #sars-cov-2